Disclosure in terms of Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015

Novartis India Limited July 29, 2026 The Secretary BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 500 672 Subject: Disclosure in terms of Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. Dear Sir/ Madam, Pursuant to Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, please find enclosed herewith the disclosure in Form C received from Novartis AG, Erstwhile Promoter of the Company, in respect of the Sale of 1,74,50,680 (One Crore Seventy-Four Lakhs Fifty Thousand Six Hundred and Eighty Only) equity shares of the Company representing 70.68% (Seventy point Sixty-Eight) of the share capital. The disclosure was received by the Company on Wednesday, July 29, 2026. The disclosure will also be made available on the Company’s website at www.nilpharma.co.in. Kindly take the above information on record and acknowledge receipt. Yours sincerely, For Novartis India Limited Chandni Maru Company Secretary and Compliance Officer A60291 Encl as above: Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in Novartis AG CH-4002 Basel Switzerland https://www.novartis.com https://x.com/novartisnews July 29, 2026 The Board of Directors Novartis India Limited Inspire BKC, 7th Floor, Bandra Kurla Complex, Bandra East, Mumbai 400051, Maharashtra, India. Dear Sir, Subject: Disclosure in terms of Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 We, Novartis AG, hereby make this disclosure pursuant to Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. We request you to kindly take the above on record and acknowledge receipt. Sincerely, [Signature pages follow] Novartis AG CH-4002 Basel Switzerland https://www.novartis.com https://x.com/novartisnews Form C Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 [Regulation 7(2) read with Regulation 6(2) – Continual Disclosure] Name of Target Company : Novartis India Limited ISIN of the Company : INE234A01025 Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2): Name, PAN Category of Securities held Securities - acquired /Disposed Securities held Date(s) of Date Mode Exchange No. CIN/DIN & Person prior to post acquisition Allotment of of on which address of (Promoter/m acquisition / / disposal advice/ inti acquisit the trade with contact ember of the disposal acquisition mati ion / was nos. promoter of shares / on disposa executed group/design disposal of to l ated person / shares, Com Director specify pan s/immediate Type No. and Type No. Value Transaction Type No. and Fro To y relative of % of of (In Rs.) Type (Buy/ of % of m to/others securit shareho securi Sale/Pledge / secu sharehol etc.) y lding ty Revoke/ rity ding Invoke) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Name: Novartis Promoter E q u i t y 1 , 7 4 , 5 0 , E q u i t y 1 , 7 4 , 5 I N R S a l e N I L NIL July 29, July Off- NA AG PAN No.: Shares 680 Share 0,680 13,76,8 2026 29, market AAACN4932F shares s 8,87,28 2026 sale represen 1 ting Novartis AG CH-4002 Basel Switzerland https://www.novartis.com https://x.com/novartisnews Enterprise 70.68% Identification of the Number (UID): share CHE- capital 103.867.266 Address: Lichtstrasse 35, 4056 Basel, Switzerland Contact No.: +41 61 324 11 Details of trading in derivatives on the securities of the company by Promoter, member of the promoter group, designated person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2): Trading in derivatives (Specify type of contract, Futures or Options etc.) Exchange on Type of Contract Contract Specifications Buy Sell which the Notional Value Number of units Notional Number of units trade was (Contracts lot size) Value (Contracts lot size) executed 16 17 18 19 20 21 22 NIL NIL Note: (i) “Securities” shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015. (ii) Value of transaction excludes taxes/brokerage/any other charges. (iii) In case of Options, notional value shall be calculated based on Premium plus strike price of options. [Signature pages follow]